Hetero-bivalent agents targeting FAP and PSMA.
Srikanth BoinapallyAlla LisokGabriela LoflandIl MinnYu YanZirui JiangMin Jay ShinVanessa F MerinoLei ZhengCory BraytonMartin G PomperSangeeta Ray BanerjeePublished in: European journal of nuclear medicine and molecular imaging (2022)
<sup>64</sup>Cu-FP-L1 demonstrated high and specific tumor targeting of FAP and PSMA. This compound should enable imaging of lesions expressing FAP, PSMA, or both on the tumor cell surface or within the TME. FP-L1 can readily be converted into a theranostic for the management of heterogeneous tumors.